Beeline Medicines Raises $300M Series A Led by Bain Capital to Advance BMS‑licensed Immunology Pipeline
Beeline Medicines announced a $300 million Series A financing round, led by Bain Capital, to fund its immunology and inflammation drug pipeline licensed from Bristol Myers Squibb. The Stamford‑Boston startup will develop candidates such as afimetoran (BMS‑986256) for systemic lupus erythematosus and other early‑stage programs. The round marks the company’s formal launch.
Uluu Secures $2.1M Australian Government Grant to Scale Seaweed‑based Plastic Alternative
Perth biotech startup Uluu has been awarded a $2.1 million grant from the Australian Government’s Industry Growth Program to accelerate commercial‑scale production of its seaweed‑based plastic alternatives. The funding will enable the company to increase output tenfold and support trials with...
Biogen to Acquire Apellis in $5.6B Buyout
Biogen announced a $5.6 billion acquisition of Apellis, expanding its portfolio beyond neurology. The deal was detailed in a recent filing, confirming the transaction is set to close. The acquisition positions Biogen in new therapeutic areas.
Revolution Medicines Raises $2B in Concurrent Stock and Debt Offerings
Revolution Medicines announced a $2 billion financing, combining a stock offering and debt issuance, to fund its development of daraxonrasib for advanced pancreatic cancer. The raise exceeds the company's original target and supports further clinical progress.
StarLight Therapeutics Secures $2.0M Seed Funding
European venture studio AQYLA BioVentures launched its first programme, STARLIGHT Therapeutics, which secured €1.8 million (approx $2.0 million) in seed funding. The round supports the development of retinal disease therapies and was announced as part of AQYLA's new biotech venture studio model.
Clean Food Group Secures $6.5M Investment to Scale Yeast‑based Oils
Clean Food Group has raised £4.5 million ($5.6 million) in equity from Clean Growth Fund and New Agrarian, plus a £700,000 ($0.9 million) non‑dilutive grant from Innovate UK. The funding will accelerate the ramp‑up of its world‑largest yeast‑based oils and fats facility in Knowsley,...
Alamar Biosciences Files for up to $154M Nasdaq IPO
Alamar Biosciences, a California biotech developing a proteomics‑based biomarker platform, announced plans to sell 9.4 million shares at $15‑$17 each on Nasdaq under the ticker ALMR, targeting a raise of $133‑$154 million to fund commercial expansion and manufacturing capacity.
Harbinger Health Raises $100M to Advance Cancer Detection Technology
Harbinger Health, a startup developing cancer‑detection tests, announced a $100 million financing round to accelerate its technology. The funding will support further development and commercialization of its cancer‑detection platform. The round was announced on April 14, 2026.
Eli Lilly to Acquire CrossBridge Bio for up to $300M
Eli Lilly announced on Tuesday it will acquire cancer‑focused antibody‑drug conjugate startup CrossBridge Bio for up to $300 million. The deal, involving biotech entrepreneur Michael Torres, aims to strengthen Lilly’s oncology pipeline. The acquisition was disclosed on 14 April 2026.
Reme-D Secures $500,000 From Global Innovation Fund to Expand Molecular Diagnostics
Egyptian biotech startup Reme-D, which develops room‑temperature PCR testing kits, has raised $500,000 from the Global Innovation Fund. The funding will be used to scale manufacturing, expand into Nigeria and Libya, and advance R&D in genetic disease, oncology, and maternal...
NeoMorph Raises $100M for Molecular Glues
San Diego-based NeoMorph announced a $100 million funding round to advance its molecular glue drug discovery platform. The capital will support further development and clinical programs. The round was announced on April 13, 2026.
Oricell Therapeutics Raises $110M in Pre-IPO Financing
Oricell Therapeutics, a China-based developer of CAR‑T therapies for solid tumors, announced it has raised over $110 million in a pre‑IPO financing round. The capital will fund the advancement of its GPC3‑targeted autologous CAR‑T program and support the company's planned public...
DeepCyte Raises $1.5M Seed Round to Advance AI-Driven Single-Cell Toxicology
DeepCyte, a techbio startup, announced the close of a $1.5 million seed round to fund its AI-powered toxicology platform MetaCore and the DeeImmuno solution for drug development. The funding will support scaling the high-throughput single-cell metabolomics technology and further AI...
Basilea Pharmaceutica Secures $6M Non‑dilutive Grant From CARB‑X for Novel Antibiotic BAL2420
Swiss biotech Basilea Pharmaceutica announced it has received an additional US$6 million non‑dilutive grant from the non‑profit accelerator CARB‑X to fund the Phase I trial of its novel Gram‑negative antibiotic BAL2420. The funding follows six years of CARB‑X support and enables the...
Avalyn Pharma Files for IPO to Fund Pulmonary Fibrosis Treatments
Avalyn Pharma, a biotech developing inhaled formulations of approved pulmonary fibrosis drugs, announced it has filed for an initial public offering. The company aims to raise capital to fund its late-stage development work and bring its treatments to market.
